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Division of Nephrology, Department of Medicine, University of California, Irvine, I,vine, California, USA
Down-regulation of VLDL receptor expression in chronic experimental
renal failure. VLDL receptor (VLDL-R) is a novel member of the LDL
receptor gene family with distinct tissue distribution and function. It binds
and internalizes VLDL particles and is primarily expressed in skeletal
muscle, heart, brain and adipose tissue, which use fatty acids for energy
production or storage. CRF is associated with elevated serum triglyceride
and VLDL concentrations and depressed VLDL and chylomicron clear-
ance. We have recently shown marked down-regulation of lipoprotein
lipase expression in CRF. This study was conducted to test the hypothesis
that VLDL-R expression may be similarly depressed in CRF. To this end,
VLDL-R mRNA (Northern blot) and protein mass (Western blot) of
skeletal muscle (soleus) and heart were measured in male Sprague-
Dawley rats six weeks after 5/6 nephrectomy (CRF group) or sham
operation (NL group). A group of erythropoietin (EPO)-treated (150
U/kg twice weekly) CRF animals was included to determine the possible
effect of EPO-deficiency anemia (EPO-CRF group). Subgroups of animals
were studied at weeks 1, 3 and 6. The CRF group showed a fivefold
increase in plasma triglyceride concentration. This was associated with an
impressive fourfold reduction in heart and skeletal muscle VLDL-R
mRNA and protein mass. VLDL-R mRNA levels in the heart and skeletal
muscle were directly related to creatinine clearance and inversely related
to serum triglyceride and VLDL concentrations. EPO therapy led to a
mild improvement in CRF hypertriglyceridemia but failed to improve
VLDL-R expression. Thus, the rise in plasma triglyceride and VLDL
concentrations in CRF animals was associated with marked down-regula-
tion of VLDL-R expression. Down-regulation of VLDL-R expression,
shown here for the first time, reveals another facet of disturbed lipid
metabolism in CRF.
Chronic renal failure (CRF) frequently results in hypertriglyc-
eridemia and elevated plasma concentration of very low density
lipoprotein (VLDL), coupled with impaired clearance of VLDL,
chylomicrons and their remnants [1—61. The latter has been
attributed to depressed lipoprotein lipase (LPL) and hepatic
lipase (HL) activities. These abnormalities are thought to be
primarily due to decreased plasma concentration of Apo C-Il
which is necessary for LPL activation [7—12] together with in-
creased plasma concentrations of lipase inhibitors, Apo C-Ill and
pre-/3-HDL in CRF [13—16], In a recent study, we have shown a
progressive down-regulation of heart, skeletal muscle and adipose
tissue LPL expression in rats following 5/6 nephrectomy [171.
Takahashi et al recently cloned a cDNA from rabbit heart
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encoding for a protein with substantial sequence homology with
LDL receptor [18]. However, when expressed in vitro, the protein
avidly bound and internalized VLDL but had no affinity for LDL.
Based on its specific affinity for VLDL, the receptor was named
VLDL receptor (VLDL-R). The primary structural difference
between LDL receptor and VLDL-R is that the ligand binding
domain of VLDL-R consists of eight tandem copies of 40
cysteine-rich amino acid repeats as opposed to seven repeats in
the LDL receptor protein [19]. This minor structural difference is
responsible for the specific ligand binding properties of the two
closely related receptors. From the functional standpoint, LDL-R
binds lipoproteins through Apo B-100 in LDL particles or Apo E
in intermediate density lipoprotein (IDL), /3-migrating VLDL
(f3-VLDL) and VLDL particles. In contrast, VLDL-R binds Apo
E-containing lipoproteins but not LDL [20—23]. In addition to
their different ligand binding properties, VLDL-R and LDL-R
have distinctly different tissue distributions. Thus, in contrast to
LDL-R which is primarily expressed in the liver, adrenal cortex,
testes and ovaries, VLDL-R is mainly expressed in skeletal
muscle, heart, adipose tissue and brain, tissues that utilize fatty
acids for energy metabolism [18, 24]. In this regard, tissue
distribution of VLDL-R is remarkably similar to that of LPL
which catalyzes the hydrolysis of triglycerides in the VLDL and
chylomicrons leading to release of free fatty acids [25]. Therefore,
it appears that, like LPL, VLDL-R may play a role in regulation
of plasma VLDL concentration and energy metabolism.
In view of the elevation of plasma concentration and impaired
clearance of VLDL particles in CRF, we hypothesized that CRF
may be associated with VLDL-R deficiency. The present study
was designed to test this hypothesis. To this end, skeletal muscle
and heart VLDL-R mRNA and protein mass were studied in rats
following 5/6 nephreetomy (CRF) and sham operation (control).
The results revealed a marked down-regulation of VLDL-R
expression supporting the original hypothesis.
Methods
Animal model
Male Sprague-Dawley rats (Harlan Sprague Dawley, Inc., In-
dianapolis, IN, USA) weighing 200 to 220 g were fed Purina Rat
Chow (Purina Mills, Brentwood, MO, USA) and water ad libituin.
They were housed in a temperature and light regulated space with
12-hour day (500 lux) and 12-hour night (< 5 lux) cycles. The
animals were randomly assigned to the CRF and normal control
groups. Animals randomized to the CRF group were subjected to
5/6 nephrectomy. Under general anesthesia with pen tobarbital, 50
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Table 1. Serum concentrations of total cholesterol, VLDL cholesterol,
triglycerides and creatinine, creatininc clearance (Ce,), hematocrit and
systolic blood pressure in the normal control (NL) rats and those with
chronic renal failure treated with placebo (CRF) or EPO (CRF/EPO)
NL CRF CRF/EPO P
____ ____
(N 6) (N = 6) (N = 6) (ANOVA)
Serum cholesterol 63.9 4.1) 178.2 11.5° 140.8 7.1° < 0.001
mg/dl
Serum VLDL 8.7 0.3 43.5 6.1° 33.9 1.8° <0.001
mg/dl
Serum triglycerides 43.5 1.6 209.0 22.9 166.1 9.4° < 0.001
mg/dl
Serum creatinine 0.6 0.1 2.9 0.3° 3.0 0.2 <0.001
mg/dl
Ccr mI/mm 1.5 0.2 0.5 0.04° 0.7 0.1° <0.001
Hematocrit % 46.5 1.5 38.1 0.6° 51.1 1.5 <0.001
Urinary protein 7.9 0.7 35.0 5.0° 34.0 2.7° <0.01
mg/24 hr
Blood pressure 107.5 3.6 143.7 4.6° 180.0 7.1' <0.001
mm Hg
________________________________
Data are given as mean SEM.
a P < 0.05 vs. control group
5P < 0.05 vs. CRF group
mg/kg IP, 2/3 of the left kidney was surgically excised through a
dorsal incision. This was followed by removal of the right kidney
four days later. Animals assigned to the normal control group
underwent sham operation. Strict hemostasis and aseptic mea-
sures were observed during surgery. Subgroups of animals were
studied at weeks 1, 3 and 6 following nephrectomy or sham
operation. Blood pressure was determined by rat tail plethysmog-
raphy (Harvard Apparatus, South Natick, MA, USA). A 24-hour
urine collection was obtained for measurement of creatinine
clearance and protein excretion prior to final experiment. Under
general anesthesia the animals were killed by exsanguination, and
heart and soleus muscle were removed immediately. Serum
concentrations of cholesterol, triglycerides, VLDL-cholesterol,
creatinine and urinary protein were measured using standard
laboratory techniques.
Regular administration of erythropoietin (EPO) has been
shown to mitigate hyperlipidemia in patients with end-stage renal
disease [26]. In order to determine if the effect of EPO therapy is
mediated by possible modification of VLDL-R expression, a
group of EPO-treated CRF animals was included. These animals
were given intraperitoneal injections of recombinant EPO, 150
units twice a week for six weeks. The EPO dosage employed here
was based on our earlier studies which demonstrated that the dose
given was sufficient to prevent anemia of CRF in this model [27].
Polyrnerase chain reaction (PER)
A partial eDNA probe for rat VLDL-R was prepared by PCR.
To this end, two oligonucleotide primers were used to amplify a
502 hp rat VLDL-R eDNA fragment. The primers used included
VLDL-Ri (nucleotide 361 to 383: 5' GATGCiCAGTGAC-
GAGAAGAAC1 3') and VLDL-R2 (nucleotide 841 to 863: 5'
CAAGAGACTCGTCTGATTGGTC3'). The nucleo tide compo-
sitions of these primers were derived from a published rat
VLDL-R sequence [28]. First strand eDNA was synthesized from
I .tg rat heart poly(A ') RNA (used as template) employing a
cDNA cyclic kit (In vitrogene, San Diego, CA, USA). The eDNA
was then amplified by PCR in 50 p.l of a solution containing 10 mrvi
Tris-HCI, 50 mM KC1, 1.5 mi MgCl, 200 I.LM dNTP mixture, I U
Taq polymerase and 1 j.LM of each primer. PCR amplification was
carried out for 30 cycles according to the following steps: 94°C,
one minute; 55°C, one minute; and 72°C, one minute. The PCR
products were separated on 1% agarose gel, and the band
corresponding to the 500 base pairs was cut, isolated with a
Gene-Clean 228 II Kit (Qiagen Inc., Chatsworth, CA, USA), then
ligated to a PCR 228 II vector using a TA cloning kit (Invitro-
gene). Positive insert was sequenced by Sequenase Version 2.0 Kit
(United States Biochemical Co., Cleveland, OH, USA) on double
stranded DNA. To prepare the probe, approximately 0.5 Kb
VLDL-R eDNA insert was excised by EcoRI from the above
clone.
RNA preparation and Northern blot analysis
The rats were killed between 9 and ii a.m. The tissues were
removed immediately, frozen in liquid nitrogen and stored at
—70°C until processed. Total RNA was prepared from 1 g of
tissue with RNAzol using the manufacturer's recommended pro-
cedure (Tel-Test Inc., Friendswood, TX, USA) as previously
described [29]. RNA concentration was determined from the
absorbance at 260 rim using a spectrophotometer (Gene-Quat,
Bio-Rad, Hercules, CA, USA). Twenty-five microgram aliquots of
total RNA were denatured in 2.2 M formaldehyde at 65°C for 15
minutes and run on 1.0% agrose/2.2 M formaldehyde gel at 46 V
for four hours. The separated RNA was transferred to the nylon
membrane (Zeta probe; Bio-Rad) by capillary blotting in 6 1< SSC
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Fig. 1. A representative autoradiograph of the Northern blots of muscle and
heart VLDL-R and the corresponding GAPDH in the normal control (NL)
(lane 1) and the uremic rats (CRF) at weeks 1 (lane 2), 3 (lane 3), and 6
(lane 4). Total RNA (25 jzg/lane) was isolated from muscle and heart as
described in the Methods section and separated by electrophoresis on
1.0% agarose/2.2 M formaldehyde gel. RNA was transferred to a nylon
filter and hybridized with the 32P-labeled 0.5 Kb eDNA to rat VLDL-R
mRNA and 1.3 Kb eDNA to rat GAPDH mRNA used to control for
possible variations in the loading dose.
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buffer overnight and immobilized by UV irradiation (Ultraviolet
Crosslinker; Fisher Scientific, Pittsburgh, PA, USA). The mem-
brane was incubated at 65°C in a solution containing 5 X SSPE,
5 X Denhard's, 1% SDS and 100 g/ml salmon sperm DNA for
two hours. The cDNA probe for rat glyceraldehyde phosphate
dehydrogenase (GAPDH) (1.3 Kb PstI fragment) was obtained
from American Type Culture Collection (Rockville, MD, USA).
The cDNA probe for VLDL-R was prepared as described above.
The probes were labeled with [32P] dCTP (3000 Ci/mmol; New
England Nuclear Inc., Boston, MA, USA) by the random primer
method (Promega Inc., Madison, WI, USA). Hybridization was
carried out at 60°C in a prehybridization solution with 32P labeled
eDNA. The blots were washed twice in 2 X SSPE/0.5% SDS
solution at room temperature, twice in I X SSPEIO.5% SDS
solution at 37°C, and twice in 0.1 X SSPEIO.5% SDS solution at
65°C, for 15 minutes each. The washed blots were exposed to x-ray
film (New England Nuclear Inc.) at —80°C for two to six hours for
GAPDH and two to three days for VLDL-R. The autoradio-
graphs were scanned with a laser densitometer (Molecular Dy-
namics, Sunnyvale, CA, USA) to determine relative mRNA levels.
The values obtained for constitutively expressed GAPDH gene
were used as an internal control.
Monoclonal antibody production
The hybridoma cell line, IgG-6A6, producing mouse monoclo-
nal antibody recognizing the cytoplasmic domain of the VLDL-R
from various tissues and species was purchased from ATCC. The
hybridoma was grown in Dulbecco's Modified Eagle's Medium
(DMEM; Gibco BRL Products, Gaithcrsburg, MD, USA) with
10% FCS. The cells were then subcultured and allowed to
overgrow until cell death occurred. The supernatant containing
the antibody was harvested and stored.
Western blot analysis
Muscle and heart plasma membranes were prepared as follows:
frozen rat tissues were homogenized in 20 mivi Tris-HCI (pH 7.5)
containing 2 mivi MgCl2, 0.2 M sucrose, 5 mM phenylmethylsulfonyl
fluoride, 5 g/ml leupeptin, 10 g/ml aprotinin and 3 tg/ml
1
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Fig. 2. Representative Western blot of muscle and heart VLDL-R in the normal
control (NL) (lane 1), the placebo-treated uremic rats (CRF) (lane 2) and
EPO-treated rats (CRFIEPO) (lane 3) obtained at week 6. Membrane polypep-
tides (100 jzgllane) were isolated from muscle and heart and size-fractionated
on 4 to 1.2% Tris glycine gel, transferred to ECL membrane and immuno-
blotted using mouse monoclonal VLDL-R antibody.
A
GAPDH
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Fig. 4. Representative Northern blot of muscle and heart VLDL-R and the
corresponding GAPDH in the normal control group (NL, lane 1), placebo-
treated uremic rats (CRF, lane 2) and EPO-treated uremic rats (CRFIEPO,
lane 3).
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Fig. 3. Longitudinal measurements of (A') muscle and (B) heart VLDLR
mRNA (normalized against corresponding GAPDH mRNA) in the normal
control solid line, N 6) and uremic rats (dotted line) at weeks 1, 3 and 6
(N = 6). Data are given as mean SCM. °P < 0.02.
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pepstatin A. The crude extracts were centrifuged at 3000 >< g for
10 minutes at 4°C. The supernatant was then centrifuged at
35,000 x g for 30 minutes. The crude membrane preparations
were washed with the above buffer and centrifuged at 35,000 g for
45 minutes at 4°C. Protein concentration was determined using a
Bio-Rad Kit (Bio-Rad Laboratories). One-hundred microgram
protein aliquots were size-fractionated on 4 to 12% Tris-glycine
gel (Novex, San Diego, CA, USA) at 120 V for two hours. After
electrophoresis, proteins were transferred to Hybond-ECL mem-
brane (Amersham Life Science Inc., Arlington Heights, IL, USA).
The membrane was incubated for one hour in buffer A (1 X PBS,
0.1% Tween-20 and 8% nonfat milk) and then overnight in the
same buffer to which 1:10 dilution of the above antibody prepa-
ration were added. The membrane was washed once for 15
minutes then twice for five minutes in I >< PBS, 0.1% Tween-20
prior to a one-hour incubation in buffer A to which diluted
(1:1000) horseradish peroxidase-linked sheep anti-mouse IgG
(Amersham) was added. The washes were repeated before the
membranes were developed with chemiluminescent agents (ECL;
Amersham) and subjected to autoradiography for one hour.
Data analysis
Analysis of variance (ANOVA), Student's 1-test and regression
analysis were performed in evaluation of the data. P values equal
to or less than 0.05 were considered significant. Data are pre-
sented as mean SCM.
Results
General data
Data are shown in Table 1. As expected, the CRF group
exhibited a significant rise in arterial blood pressure and a marked
increase in serum creatinine, triglyceride, total cholesterol and
VLDL-cholesterol concentrations. In addition, the CRF group
showed an expected fall in creatinine clearance and hematocrit as
well as mild proteinuria. EPO therapy prevented the CRF-
associated anemia and compounded the severity of hypertension
as previously shown to occur in this model [271.
VLDL-R mRNA and protein mass
Data are illustrated in Figures 1, 2, and 3. The CRF group
showed a steady decline in heart and skeletal muscle VLDL-R
mRNA beginning one week postnephrectomy. This led to an
impressive fourfold reduction in heart and skeletal muscle
VLDL-R mRNA levels by week 6. The reduction in VLDL-R
mRNA in the CRF group was accompanied by a parallel decline
in VLDL-R protein mass of virtually the same magnitude. Thus,
the observed down regulation of VLDL receptor in the CRF
animals appears to occur at the level of mRNA.
Effect of EPO therapy
[)ata are depicted in Figures 2, 4 and 5 and Table 1, EPO
therapy resulted in a mild attenuation of CRF-induced hypertri-
glyccridemia. However, EPO therapy had no discernible effect on
either VLDL-R mRNA or protein mass of the heart or skeletal
muscle. Thus, EPO therapy had a minimal effect on plasma
triglyceride and VLDI. levels and no demonstrable effect on
VLI)L-R expression.
Correlations
Data arc illustrated in Figures 6 through 9. A significant direct
correlation was found between VLDL-R mRNA and creatinine
clearance in the study animals. VLDL-R mRNA values were
inversely related to serum VLDL and serum triglyceride concen-
trations in the study animals. A strong positive correlation was
found between VLDL-R mRNA and protein mass.
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Fig. 5. Comparison of muscle and heart VLDL-
RIGAPDH mRNA and protein mass in the
nortnal control group (NL, N = 6), placebo-
treated uremic rats (CRF, N = 6) and EPO-
treated uremic rats (CRF/EPO, N = 6) obtained
at week 6. Data are given as mean SCM. *V <
0.001 vs. NL group.
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Fig. 7. Correlation between serum VLDL concentration and muscle (A r =
—0.81; P < 0.01) and heart (B; r = —0.76; P < 0.01) VLDL-R/GAPDH
mRNA obtained in the normal control group (•, N = 6)and uremic rats (U)
studied at weeks 1, 3 and 6 postnephrectomy.
use fatty acids as a main source of energy production (such as
myocytes) or storage (such as adipose tissue). If true, CRF-
induced VLDL-R deficiency can compound the effects of lipopro-
tein lipase and hepatic lipase deficiencies known to occur in renal
insufficiency [7—17]. Lipoprotcin lipase and hepatic lipase are
members of a large lipase gene family which includes pancreatic
lipase as well [251. These endothelial-bound enzymes catalyze the
hydrolysis of triglycerides contained in chylomicrons and VLDL
particles to release free fatty acids for consumption or storage by
the underlying myocytes or adipocytes. Earlier studies have
revealed a marked LPL and hepatic lipase deficiency in patients
and animals with renal failure [7—17, 30]. Deficiency of these
enzymes has been linked to impaired clearance of VLDL and
chylomicrons, elevation of plasma VLDL and triglyceride concen-
trations, triglyceride enrichment of various lipoproteins and re-
duced triglyceride contents of the adipose tissue in CRF [1—6, 10,
31, 32]. Secondary hyperparathyroidism and increased concentra-
tions in the plasma of the lipase inhibitors, Apo C-TI! and
prc-3-HDL, have been implicated in the pathogenesis of CRF-
induced deficiency of these enzymes [8, 16]. However, in a recent
Fig. 6. Correlation between creatinine clearance and muscle (A, r = 0.70,
P < 0.05) and heart (B; r = 0.76; P < 0.05) VLDL-R/GAPDH mRNA
obtained in the normal control group (I N 6) and uremic rats (•) studied
at weeks 1, 3 and 6.
Discussion
The marked rise in plasma triglyceride and VLDL concentra-
tions during the observation period was accompanied by a severe
progressive decline in VLDL-R expression of the heart and
skeletal muscle in the CRF animals. In contrast, VLDL-R expres-
sion was virtually constant in the sham-operated control animals
during the same period. This observation clearly indicates that the
fall in VLDL-R must be due to the renal insufficiency as opposed
to the possible effect of either the surgical procedure or the aging
process. This conclusion is further supported by the strong
correlation found between creatinine clearance and VLDL-R
values in the study population.
The strong negative correlation between VLDL-R expression
and plasma concentrations of VLDL and triglycerides in the
present study suggests (but does not prove) the possible contri-
bution of acquired VLDL-R deficiency to the pathogenesis of
CRF-induced dyslipidemia. This supposition is particularly fa-
vored by the well-defined ligand binding specificity of this receptor
for VLDL particles and its primary distribution in tissues, which
918 Vaziri and Liang: VLDL receptor deficiency in uremia
z
EI0ci)
-J0
-J
>
z
EI00
0
0
-J
>
z
'I
EIC
a-
0I
-C
-J
>
zI
EItoc1 Qci) <10I
C
-I>
A
2 2
ci)
C)(I)
A
• I I
o 200 400 600 800 1000
B
0 50 100 150 200 250
B3.
2
0 50 100 150 200 250
3
2
:
0 200 400 600 800 1000
Serum triglyceride concentration, mg/dl VLDL-R protein mass, relative optical densities
Fig. 8. Correlation between serum triglyceride concentration and muscle (A, Fig. 9. Correlation between muscle (A, r = 0.72; P <0.05) and heart (B; r =
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GAPDH mRNA obtained in the normal control group ( N = 6) and uremic
rats •) studied at week 6.
study, we have shown a marked down-regulation of LPL expres- renal disease [261. The EPO-treated animals employed in the
sion in skeletal muscle, heart and adipose tissue of rats with CRF present study showed a mild reduction in plasma triglyceride and
[171. This observation extends the mechanism of LPL deficiency VLDL concentrations relative to values found in the placebo-
beyond its enhanced inactivation in CRF. Severe VLDL-R defl- treated CRF animals. However, correction of anemia with EPO
ciency, demonstrated in the present study, compounds the previ- therapy did not alter VLDL-R expression in the CRF animals
ously known effects of LPL and HL deficiencies on VLDL employed in the present study. Thus, EPO-deficiency anemia does
metabolism in CRF. not appear to he responsible for the observed down regulation of
The mechanism by which CRF leads to VLDL-R deficiency is VLDL-R expression.
uncertain and requires further investigation. The CRF animals Tn a recent study, we have shown marked down-regulation of
showed a slight reduction of food intake and a slower growth rate VLDL-R expression in rats with puromycin-induced nephrotic
as compared to the normal control animals. Uowever, prolonged syndrome and normal creatinine clearance [33], The CRF animals
fasting has been shown to have no significant effect on VLDL-R employed here exhibited mild proteinuria. However, the degree of
expression in rats [28]. Moreover, diminished food intake is proteinuria in these animals was far below the nephrotic range
normally associated with a decline in plasma triglyceride and seen in animals with puromycin-induced nephrotic syndrome [34].
VLDL levels [281 as opposed to the markedly elevated values Thus, mild proteinuria in CRF animals is an unlikely cause of the
found in CRF, Therefore, reduced food intake does not appear to observed VLDL-R deficiency.
be a likely culprit. It is of interest that gene expression of several other proteins,
Correction of anemia with EPO therapy has been shown to such as PTH-rP receptor, hepatic lipase and LPL have been
partly ameliorate CRF dyslipidemia in patients with end-stage shown to be depressed in experimental CRF [17, 35,361. These
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observations together with the finding of down-regulation of
VLDL-R expression in the present study might be indicative of a
diffuse down regulation of mRNA production in uremia.
In conclusion, the rise in plasma triglyceride and VLDL con-
centrations in the course of experimental CRF was accompanied
by a marked decline in heart and skeletal muscle expression of
VLDL-R. The acquired down-regulation of VLDL-R, shown for
the first time here, may play a role in CRF-induced dyslipidemia.
The mechanism responsible for depressed VLDL-R expression in
CRF is unclear. Further studies are planned to address this issue.
Reprint requests to N.D. Vaziri, M.D., Division of Nephrologt, UCI
Medical Center, 101 The City Drive, Orange, California 92668, USA.
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